Alirocumab vs QLC7401
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Alirocumab · Praluent
Marketed by Regeneron Pharmaceuticals and partners
NCT01507831 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 trial (ODYSSEY LONG TERM) gave alirocumab 150 mg or placebo every 2 weeks for 78 weeks, on top of maximum tolerated statins, to 2,341 patients at high cardiovascular risk. Its registered primary objective and primary outcome are long-term safety and tolerability, which have no formal efficacy test, so the registered primary has no met or missed result. The published paper reports the efficacy end point it pre-specified: LDL cholesterol fell 62 percentage points more with alirocumab than with placebo at week 24 (P<0.001). Sources: CT.gov posted results and the peer-reviewed paper (Robinson et al., N Engl J Med 2015). Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07477704 (registry estimate)
Reported efficacy
DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand (Baseline, Week 24): DB Period: Alirocumab Q2W -33.6 percent change (Standard Error 3.4) | Db Period: Alirocumab Q4W -38.2 percent change (Standard Error 4) vs DB Period: Placebo Q2W 9.7 percent change (Standard Error 4.3) | Db Period: Placebo Q4W -4.4 percent change (Standard Error 3.7) (met)
Result source: NCT03510884
QLC7401
Developed by Suzhou Ribo Life Science and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2027 · NCT07444086 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alirocumab | QLC7401 |
|---|---|---|
| LDL-C, % change | -52.7% vs -0.3%−52.4 vs placeboNCT01926782165 other results
| —Trial running · NCT07444086 |
| Non-HDL-C, % change | -51.6% vs 0.7%−52.3 vs placeboNCT0150783187 other results
| —Trial running · NCT07444086 |
| ApoB, % change | -52.8% vs 1.2%−54 vs placeboNCT0150783186 other results
| —Trial running · NCT07444086 |
| Lp(a), % change | -29.3% vs -3.7%−25.6 vs placeboNCT0150783164 other results
| —Trial running · NCT07444086 |
| 3-point MACE (% with event) | —Not posted · NCT04790513 | —Trial running · NCT07444086 |
LDL-C, % change
- Alirocumab
- -52.7% vs -0.3%−52.4 vs placeboNCT01926782
165 other results
- -58.8% vs -0.1% NCT01926782
- -45.7% vs -6.6% NCT01617655
- -48.2% vs -2.3% NCT01644175
- -48.8% vs 9.1% NCT01623115
- -48.7% vs 2.8% NCT01709500
- -48.2% vs 0.8% NCT02585778
- -51.7% vs 4.7% NCT02023879
- -26.9% vs 8.6% NCT03156621
- -43.8% vs -4.3% NCT02584504
- -70.1% vs -4.3% NCT02584504
- -50.2% vs -0.3% NCT01926782
- -51.6% vs -0.1% NCT01926782
- -51.8% vs 0.8% NCT02585778
- -57.1% vs 6.3% NCT02289963
- -62.5% vs 1.6% NCT02107898
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -50.6% vs -20.7% NCT01644188
- -56% vs -20.3% NCT02715726
- -47.2% vs -15.6% NCT01644474
- -45% vs -14.6% NCT01709513
- -50.6% vs -15.9% NCT01730053
- -36.3% vs -15.9% NCT01730053
- -44.1% vs -5% NCT01730040
- -54% vs -5% NCT01730040
- -23.5% vs 16.4% NCT01663402
- -40.1% vs 14.6% NCT01663402
- -45.7% vs 8% NCT01663402
- -52.8% vs 8.2% NCT01663402
- -55.8% vs 4.4% NCT01663402
- -58.3% vs 4.4% NCT01663402
- -52.4% vs 3.6% NCT01507831
- -58% vs 3.9% NCT01507831
- -56.8% vs 4.4% NCT01507831
- -59.9% vs 4.6% NCT01507831
- -61% vs 0.8% NCT01507831
- -62.8% vs 0.7% NCT01507831
- -57.8% vs 3.5% NCT01507831
- -63.3% vs 1.5% NCT01507831
- -64.2% vs 1.4% NCT01507831
- -59.4% vs -0.4% NCT01926782
- -62.3% vs -0.3% NCT01926782
- -58.4% vs 0.3% NCT01926782
- -55.3% vs 1.1% NCT01926782
- -60% vs -0.5% NCT01926782
- -58% vs 1.4% NCT01926782
- -40.3% vs 11.5% NCT01623115
- -43.7% vs 14% NCT01623115
- -47.1% vs 9% NCT01623115
- -48.1% vs 9.1% NCT01623115
- -50.3% vs 8.4% NCT01709500
- -43.5% vs 5.7% NCT01623115
- -40.9% vs -0.2% NCT01617655
- -42.1% vs -3% NCT01617655
- -42% vs -2.9% NCT01617655
- -42.5% vs 0.5% NCT01644175
- -45.5% vs -6.6% NCT01617655
- -50.7% vs -0.8% NCT01644175
- -43.9% vs 5.7% NCT01623115
- -46.9% vs -6.6% NCT01617655
- -46.9% vs -6.6% NCT01617655
- -46.3% vs 1.1% NCT01644175
- -47.6% vs 1.7% NCT01644175
- -54.6% vs 5.1% NCT02023879
- -43.4% vs -2.8% NCT02584504
- -70.1% vs -2.8% NCT02584504
- -54.2% vs -3.7% NCT02584504
- -69.9% vs -3.7% NCT02584504
- -54% vs -2.6% NCT02584504
- -69.9% vs -2.6% NCT02584504
- -41.7% vs 3.2% NCT02023879
- -44.8% vs 3.6% NCT02023879
- -52.3% vs 3.2% NCT02023879
- -55% vs 3.6% NCT02023879
- -62.5% vs -3.6% NCT02107898
- -64.6% vs -3.4% NCT02107898
- -49.3% vs 8.8% NCT01623115
- -49.4% vs 2.7% NCT01709500
- -55.3% vs 5.1% NCT02023879
- -50.9% vs 0.7% NCT02585778
- -43.3% vs 2.4% NCT02585778
- -63.7% vs 1.7% NCT02107898
- -43.8% vs 4.6% NCT01709500
- -44.2% vs 4.6% NCT01709500
- -48.8% vs 1.4% NCT02585778
- -44.8% vs -0.8% NCT02585778
- -42.3% vs 4% NCT02326220
- -26.9% vs 8.6% NCT03156621
- -53.7% vs 1.6% NCT02326220
- -54.6% vs -0.4% NCT01926782
- -55.1% vs -0.3% NCT01926782
- -53.8% vs 0.7% NCT02585778
- -64.2% vs -2.7% NCT02107898
- -49.4% vs 2.4% NCT02585778
- -60.2% vs 6% NCT02289963
- -51.8% vs 0.3% NCT01926782
- -45.3% vs 1.1% NCT01926782
- -53.9% vs -0.5% NCT01926782
- -47.3% vs 1.4% NCT01926782
- -50.8% vs 3.2% NCT02023879
- -51.5% vs 3.6% NCT02023879
- -49.4% vs 1.4% NCT02585778
- -46.7% vs -0.8% NCT02585778
- -57.9% vs 4.7% NCT02289963
- -58.4% vs 4.7% NCT02289963
- -64.8% vs -2.8% NCT02107898
- -53.6% vs 3.2% NCT02023879
- -54.1% vs 3.6% NCT02023879
- -37.9% vs 1.2% NCT01617655
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -33.6% vs -4.4% NCT03510884
- -38.2% vs -4.4% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -34.8% vs 2.3% NCT03510884
- -39.2% vs 2.3% NCT03510884
- -35.4% vs -3.8% NCT03510884
- -42% vs -3.8% NCT03510884
- -35.4% vs -3.8% NCT03510884
- -42% vs -3.8% NCT03510884
- -44.2% vs -15.2% NCT01644188
- -48.9% vs -17% NCT01644188
- -49.5% vs -18.3% NCT01644188
- -51.8% vs -19.7% NCT01644188
- -52.4% vs -21.8% NCT01644188
- -51.2% vs -21.8% NCT01644188
- -52.4% vs -22.7% NCT01644188
- -58.7% vs -21.3% NCT02715726
- -57.1% vs -22.2% NCT02715726
- -58.1% vs -22.7% NCT02715726
- -48.1% vs -19.6% NCT01644474
- -52.2% vs -17.1% NCT01709513
- -47.3% vs -15.2% NCT01709513
- -47% vs -15.6% NCT01709513
- -51.2% vs -18% NCT01709513
- -53.5% vs -17% NCT01730053
- -41.5% vs -17% NCT01730053
- -48.6% vs -6.1% NCT01730040
- -57.8% vs -6.1% NCT01730040
- -49.6% vs -22.1% NCT01730053
- -32.3% vs -22.1% NCT01730053
- -52.6% vs -22.9% NCT01730053
- -35.1% vs -22.9% NCT01730053
- -48.4% vs -8.5% NCT01730040
- -50.5% vs -8.5% NCT01730040
- -53.7% vs -9.2% NCT01730040
- -50.9% vs -9.2% NCT01730040
- -66.2% vs -51.2% NCT03415178
- -73% vs 2% NCT02938949
- -46.2% vs 4% NCT02957682
- -50.4% vs 2.4% NCT02957682
- -51.4% vs 2.8% NCT02957682
- -54.2% vs 3% NCT02957682
- -49.6% vs 0.6% NCT02957682
- -43.3% vs -0.3% NCT02642159
- -41.7% vs -7% NCT02642159
- -63.9% vs -13.4% NCT02984982
- -64.5% vs -7.6% NCT02984982
- QLC7401
- —Trial running · NCT07444086
Non-HDL-C, % change
- Alirocumab
- -51.6% vs 0.7%−52.3 vs placeboNCT01507831
87 other results
- -53.1% vs 0.6% NCT01507831
- -53.7% vs 0.9% NCT01507831
- -43.3% vs -0.3% NCT01926782
- -49.7% vs 0.3% NCT01926782
- -48.9% vs 0.1% NCT01926782
- -52.6% vs 0.2% NCT01926782
- -49.9% vs -0.4% NCT01926782
- -46.5% vs 0.6% NCT01926782
- -42.8% vs 9.6% NCT01623115
- -43.3% vs 9.4% NCT01623115
- -38.4% vs 5.3% NCT01623115
- -41.9% vs -6.2% NCT01617655
- -41.7% vs -6.1% NCT01617655
- -39.1% vs -1.6% NCT01644175
- -40.9% vs -0.5% NCT01644175
- -41.4% vs -6.9% NCT01617655
- -37.4% vs 2.6% NCT01644175
- -42.6% vs 3.1% NCT01709500
- -43.2% vs 3.1% NCT01709500
- -37.9% vs 0.7% NCT02585778
- -44.2% vs 4.8% NCT02023879
- -46.7% vs 5% NCT02023879
- -36.2% vs -4.9% NCT02584504
- -61.1% vs -4.9% NCT02584504
- -35.9% vs -3.5% NCT02584504
- -61.1% vs -3.5% NCT02584504
- -34.9% vs 3% NCT02023879
- -45.3% vs 4.8% NCT02023879
- -46.9% vs 5% NCT02023879
- -45.9% vs 0.7% NCT02585778
- -47.2% vs 4.3% NCT02289963
- -50.1% vs 4.1% NCT02289963
- -54.9% vs 2.6% NCT02107898
- -56% vs 2.6% NCT02107898
- -43.4% vs 3% NCT02023879
- -47.3% vs 3.9% NCT02289963
- -56.3% vs -1.7% NCT02107898
- -35.7% vs 4.7% NCT02326220
- -24.8% vs 8% NCT03156621
- -24.8% vs 8% NCT03156621
- -47.1% vs 2.8% NCT02326220
- -41.6% vs 0.3% NCT01926782
- -37.9% vs 4.1% NCT01709500
- -43.6% vs -0.3% NCT01926782
- -47.2% vs 0.1% NCT01926782
- -44.4% vs 0.2% NCT01926782
- -45.8% vs -0.4% NCT01926782
- -37.4% vs 0.6% NCT01926782
- -31% vs -3.7% NCT03510884
- -35.6% vs -3.7% NCT03510884
- -31% vs -3.7% NCT03510884
- -35.6% vs -3.7% NCT03510884
- -33% vs 2.8% NCT03510884
- -34.7% vs 2.8% NCT03510884
- -33% vs 2.8% NCT03510884
- -34.7% vs 2.8% NCT03510884
- -42.1% vs -19.2% NCT01644188
- -43.7% vs -20.2% NCT01644188
- -42.6% vs -20.6% NCT01644188
- -47% vs -19.4% NCT02715726
- -49.1% vs -20.4% NCT02715726
- -47.4% vs -20.7% NCT02715726
- -40.6% vs -15.1% NCT01644474
- -42.5% vs -16.7% NCT01644474
- -40.2% vs -14.6% NCT01709513
- -46.9% vs -17.1% NCT01709513
- -41.5% vs -15.8% NCT01709513
- -42.7% vs -11.2% NCT01730053
- -31.4% vs -11.2% NCT01730053
- -45.7% vs -14.9% NCT01730053
- -35.6% vs -14.9% NCT01730053
- -36.7% vs -6.3% NCT01730040
- -47.6% vs -6.3% NCT01730040
- -40.5% vs -7.5% NCT01730040
- -50.5% vs -7.5% NCT01730040
- -41.2% vs -18% NCT01730053
- -29.8% vs -18% NCT01730053
- -40.6% vs -7.1% NCT01730040
- -42.3% vs -7.1% NCT01730040
- -37.3% vs -4.7% NCT02642159
- -37% vs 2.5% NCT02957682
- -40.6% vs 1.7% NCT02957682
- -41.1% vs 1.7% NCT02957682
- -44% vs 2.2% NCT02957682
- -40.4% vs 0.7% NCT02957682
- -35.5% vs -9.4% NCT02642159
- -54.5% vs -14.1% NCT02984982
- QLC7401
- —Trial running · NCT07444086
ApoB, % change
- Alirocumab
- -52.8% vs 1.2%−54 vs placeboNCT01507831
86 other results
- -54.3% vs 1.2% NCT01507831
- -55.5% vs 0.5% NCT01507831
- -40.2% vs -0.7% NCT01926782
- -45.1% vs 3.1% NCT01926782
- -44.8% vs -0.3% NCT01926782
- -47.2% vs 3.1% NCT01926782
- -46.4% vs -2.3% NCT01926782
- -41.2% vs 3.6% NCT01926782
- -41.1% vs 4.7% NCT01623115
- -41.4% vs 4.5% NCT01623115
- -34.5% vs 3.1% NCT01623115
- -39% vs -8.7% NCT01617655
- -38.9% vs -8.7% NCT01617655
- -36.7% vs -0.9% NCT01644175
- -37.9% vs -0.4% NCT01644175
- -39.2% vs -9% NCT01617655
- -34.8% vs 3.4% NCT01644175
- -42.8% vs -3.5% NCT01709500
- -43.2% vs -3.5% NCT01709500
- -33.4% vs 3.3% NCT02585778
- -38.9% vs 7.5% NCT02023879
- -40.9% vs 7.7% NCT02023879
- -32.2% vs -6% NCT02584504
- -57.9% vs -6% NCT02584504
- -31.8% vs -4.6% NCT02584504
- -58% vs -4.6% NCT02584504
- -31.3% vs 7% NCT02023879
- -39.7% vs 7.5% NCT02023879
- -41.2% vs 7.7% NCT02023879
- -39.4% vs 3.3% NCT02585778
- -42.3% vs 4.1% NCT02289963
- -45.4% vs 3.8% NCT02289963
- -55% vs -1.6% NCT02107898
- -55.9% vs -2.1% NCT02107898
- -38.4% vs 7% NCT02023879
- -40.9% vs 5.2% NCT02289963
- -54.6% vs -3.3% NCT02107898
- -33.8% vs 1.7% NCT02326220
- -22.5% vs 7.2% NCT03156621
- -22.5% vs 7.2% NCT03156621
- -42.8% vs 1.2% NCT02326220
- -36.7% vs 3.1% NCT01926782
- -35.4% vs -0.9% NCT01709500
- -39% vs -0.7% NCT01926782
- -42% vs -0.3% NCT01926782
- -38.3% vs 3.1% NCT01926782
- -40.8% vs -2.3% NCT01926782
- -33% vs 3.6% NCT01926782
- -27.4% vs -3.6% NCT03510884
- -34.3% vs -3.6% NCT03510884
- -27.4% vs -3.6% NCT03510884
- -34.3% vs -3.6% NCT03510884
- -30% vs 1.1% NCT03510884
- -31.7% vs 1.1% NCT03510884
- -30% vs 1.1% NCT03510884
- -31.7% vs 1.1% NCT03510884
- -40.7% vs -18.3% NCT01644188
- -42.1% vs -19.1% NCT01644188
- -39.7% vs -17.2% NCT01644188
- -43.5% vs -16.2% NCT02715726
- -45.2% vs -17.4% NCT02715726
- -43% vs -16.5% NCT02715726
- -36.7% vs -11% NCT01644474
- -37.3% vs -11.7% NCT01644474
- -36.3% vs -11.2% NCT01709513
- -42.6% vs -14.4% NCT01709513
- -36.1% vs -11.6% NCT01709513
- -36.5% vs -9.8% NCT01730053
- -28.3% vs -9.8% NCT01730053
- -39.5% vs -12.7% NCT01730053
- -30.4% vs -12.7% NCT01730053
- -33.7% vs -4.4% NCT01730040
- -41.9% vs -4.4% NCT01730040
- -37.7% vs -5.1% NCT01730040
- -42.7% vs -5.1% NCT01730040
- -36.1% vs -13.7% NCT01730053
- -29% vs -13.7% NCT01730053
- -38.4% vs -6.9% NCT01730040
- -36.2% vs -6.9% NCT01730040
- -36.4% vs 1.4% NCT02957682
- -39.1% vs 0.2% NCT02957682
- -39% vs 1.1% NCT02957682
- -40.9% vs 2.1% NCT02957682
- -36.7% vs 0.8% NCT02957682
- -33.8% vs -1.6% NCT02642159
- -55.1% vs -16.6% NCT02984982
- QLC7401
- —Trial running · NCT07444086
Lp(a), % change
- Alirocumab
- -29.3% vs -3.7%−25.6 vs placeboNCT01507831
64 other results
- -28.2% vs -3.1% NCT01507831
- -21.3% vs 6.4% NCT01926782
- -19.3% vs 9.8% NCT01926782
- -28.9% vs -5.5% NCT01926782
- -19.6% vs 7% NCT01926782
- -23.5% vs -8.7% NCT01617655
- -20.5% vs -5.9% NCT01644175
- -23.2% vs -1.5% NCT01617655
- -19.7% vs 0% NCT01644175
- -25.2% vs -7.5% NCT01623115
- -15.5% vs 4.1% NCT02023879
- -31.7% vs 1.3% NCT02584504
- -49.6% vs 1.3% NCT02584504
- -5.7% vs 2.2% NCT02023879
- -30.3% vs -10% NCT01709500
- -21.8% vs 4.1% NCT02023879
- -19% vs -0.5% NCT02585778
- -21.2% vs -3.9% NCT01623115
- -24.7% vs -5.6% NCT01709500
- -6.1% vs -1.2% NCT02326220
- -19.6% vs 8.8% NCT03156621
- -19.6% vs 8.8% NCT03156621
- -18.1% vs -4% NCT02326220
- -14% vs 6.4% NCT01926782
- -16.9% vs 9.8% NCT01926782
- -23% vs -0.5% NCT02585778
- -35.9% vs -2.3% NCT02289963
- -39.5% vs 2.5% NCT02107898
- -26.9% vs -5.5% NCT01926782
- -12.4% vs 7% NCT01926782
- -16.5% vs 2.2% NCT02023879
- -33.6% vs -1.7% NCT02289963
- -41.9% vs -0.5% NCT02107898
- -14.7% vs 2.5% NCT03510884
- -22.4% vs 2.5% NCT03510884
- -14.7% vs 2.5% NCT03510884
- -22.4% vs 2.5% NCT03510884
- -12.7% vs -2.5% NCT03510884
- -16% vs -2.5% NCT03510884
- -12.7% vs -2.5% NCT03510884
- -16.0% vs -2.5% NCT03510884
- -27.8% vs -6.1% NCT01644188
- -22.1% vs 1.1% NCT01644188
- -30.3% vs 4.0% NCT02715726
- -30.1% vs 6.3% NCT02715726
- -16.7% vs -12.3% NCT01644474
- -17.2% vs -14.2% NCT01644474
- -25.9% vs -7.3% NCT01709513
- -21.7% vs -4.5% NCT01709513
- -27.9% vs -5.2% NCT01730053
- -22.7% vs -5.2% NCT01730053
- -23.6% vs -20.2% NCT01730040
- -30.8% vs -20.2% NCT01730040
- -20.7% vs 3.5% NCT01730053
- -16% vs 3.5% NCT01730053
- -24% vs -11.7% NCT01730040
- -27.9% vs -11.7% NCT01730040
- -17.7% vs 4.8% NCT02957682
- -25.1% vs -1.7% NCT02957682
- -24.3% vs -1.4% NCT02957682
- -24.7% vs -0.5% NCT02957682
- -22.4% vs -3.3% NCT02957682
- -23.7% vs 3.7% NCT02642159
- -55.8% vs -17.2% NCT02984982
- QLC7401
- —Trial running · NCT07444086
3-point MACE (% with event)
- Alirocumab
- —Not posted · NCT04790513
- QLC7401
- —Trial running · NCT07444086
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QLC7401: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Alirocumab: 4 of 4 rows · QLC7401: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alirocumab |
|---|---|
| Dropout rate | 28.3%150 mg Q2Wa NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results40.3%150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —75 /up to 150 mg Q2W NCT01644175 · Phase 3 25.4%75/150 mg Q2W NCT01644175 · Phase 3 —75/Up to 150 mg Q2W NCT01623115 · Phase 3 23.8%75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 n/a: no completion milestone75 mg/up to 150 mg NCT01709500 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 12.8%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 28.1%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 16.7%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 21.6%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 9.8%150 mg Q2W NCT02326220 · Phase 3 25.5%75 /up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644188 · Phase 3 15.4%75/Up to 150 mg Q2W NCT01644474 · Phase 3 —75/Up150 mg Q2W NCT01644474 · Phase 3 0%150 mg SC Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 8.2%Q2W NCT03510884 · Phase 3 5.8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 3.7%Q4W NCT03510884 · Phase 3 22%75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 —Alirocumab NCT01663402 · Phase 3 15.5%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 0% NCT02938949 · Phase 4 · registry result, not featured evidence 9.6% NCT02984982 · Phase 4 · registry result, not featured evidence 11.2%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 12% NCT02476006 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence 5.7%New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence 6.6%75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 3.8%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 0%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 8.7%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 15.3%150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 23.8%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 9.6%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 10.3%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence —75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 8.3%75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 22.4%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 24.1%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 19.3%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 19.1%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 0%300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 41.3% NCT01576484 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 7.3%150 mg Q2Wa NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results4.2%150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 —75 /up to 150 mg Q2W NCT01644175 · Phase 3 6.2%75/150 mg Q2W NCT01644175 · Phase 3 —75/Up to 150 mg Q2W NCT01623115 · Phase 3 4%75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 3%75 mg/up to 150 mg NCT01709500 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 5.4%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 9.6%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 5.1%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 8.1%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 4.9%150 mg Q2W NCT02326220 · Phase 3 9.2%75 /up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644188 · Phase 3 9.6%75/Up to 150 mg Q2W NCT01644474 · Phase 3 —75/Up150 mg Q2W NCT01644474 · Phase 3 —150 mg SC Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 —150 Q2W NCT03156621 · Phase 3 0%Q2W NCT03510884 · Phase 3 3.8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 0%Q4W NCT03510884 · Phase 3 3.8%75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 —Alirocumab NCT01663402 · Phase 3 6.2%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence — NCT02938949 · Phase 4 · registry result, not featured evidence 4.8% NCT02984982 · Phase 4 · registry result, not featured evidence 3.6%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 4.1% NCT02476006 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence 1.5%75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 1.9%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 0%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 3.5%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 8.5%150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence —75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 18.3%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 4.9%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 2.1%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence —75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 4.9%75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 6.1%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 3.7%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 8.8%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 4.3%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination —300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence —50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 2.2% NCT01576484 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 18.7%150 mg Q2Wa NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 84 more results—150 mg Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 13.9%150 Q2W NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 12.6%75 /up to 150 mg Q2W NCT01644175 · Phase 3 —75/150 mg Q2W NCT01644175 · Phase 3 13.7%75/Up to 150 mg Q2W NCT01623115 · Phase 3 —75 mg/Up to 150 mg Q2W NCT01623115 · Phase 3 6%75 mg/up to 150 mg NCT01709500 · Phase 3 11.6%300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 —300 mg Q4W/Up 150 mg Q2W NCT01926782 · Phase 3 11.3%75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 —75 mg Q2W/Up 150 mg Q2W NCT01926782 · Phase 3 9.8%150 mg Q2W NCT02326220 · Phase 3 3.4%150 mg Q2W NCT02326220 · Phase 3 —150 mg Q2W NCT02326220 · Phase 3 —75 /up to 150 mg Q2W NCT01644188 · Phase 3 25.9%75/Up to 150 mg Q2W NCT01644188 · Phase 3 —75/Up to 150 mg Q2W NCT01644474 · Phase 3 1.9%75/Up150 mg Q2W NCT01644474 · Phase 3 —150 mg SC Q2W NCT03156621 · Phase 3 0%150 Q2W NCT03156621 · Phase 3 2.2%150 Q2W NCT03156621 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 8.2%Q2W NCT03510884 · Phase 3 3.8%Q4W NCT03510884 · Phase 3 8.7%Q2W NCT03510884 · Phase 3 6.1%Q4W NCT03510884 · Phase 3 0%Q2W NCT03510884 · Phase 3 8%Q4W NCT03510884 · Phase 3 —Q2W NCT03510884 · Phase 3 —Q4W NCT03510884 · Phase 3 —75 mg Q2W/Up to 150 mg Q2W NCT01663402 · Phase 3 23.3%Alirocumab NCT01663402 · Phase 3 17.4%75 Q2W/Up150 Q2W NCT02957682 · Phase 4 · registry result, not featured evidence 40% NCT02938949 · Phase 4 · registry result, not featured evidence 18.4% NCT02984982 · Phase 4 · registry result, not featured evidence 9.5%75 mg Q2W/Up to 150 mg Q2W NCT02642159 · Phase 4 · registry result, not featured evidence 0%150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 11.1%75 mg Q2W/up to 150 mg Q2W NCT03510715 · Phase 3 · registry result, not featured evidence 16.2% NCT02476006 · Phase 3 · registry result, not featured evidence 3%New Auto-Injector Device (Parallel NCT03415178 · Phase 3 · registry result, not featured evidence 3%New Auto-Injector Device (Single-a NCT03415178 · Phase 3 · registry result, not featured evidence —New Auto-injector Device (SYDNEY) NCT03415178 · Phase 3 · registry result, not featured evidence —75 mg Q2W/up to 150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence 10.1%75 mg Q2W/up150 mg Q2W NCT02715726 · Phase 3 · registry result, not featured evidence —150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence —150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence 3.8%150 mg Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 1.9%150 mg Q4W NCT02584504 · Phase 3 · registry result, not featured evidence 7.6%150 mg Q4W/Up Q2W NCT02584504 · Phase 3 · registry result, not featured evidence 22%75 or 150 mg Q2W NCT01954394 · Phase 3 · registry result, not featured evidence 29.2%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 26.4%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence 29.4%150 mg Q4W NCT02023879 · Phase 3 · registry result, not featured evidence —150 mg Q4W/Up to 150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 12.1%150 mg Q4W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 6.1%75 mg Q2W/Up150 mg Q2W NCT02023879 · Phase 3 · registry result, not featured evidence 9.5%75 mg/ up to 150 mg NCT01709513 · Phase 3 · registry result, not featured evidence 9%75 mg Q2W/Up to 150 mg Q2W NCT02585778 · Phase 3 · registry result, not featured evidence 17.5%75 mg Q2W/Up to 150 mg Q2W NCT02289963 · Phase 3 · registry result, not featured evidence 7%75 mg/ Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence —75 mg/Up to 150 mg Q2W NCT02107898 · Phase 3 · registry result, not featured evidence 4.1%75 mg/up to 150 mg + 10 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 7.4%75 mg/up to 150 mg + 20 mg NCT01730053 · Phase 3 · registry result, not featured evidence · combination 5.3%75 mg/up to 150 mg + Atorvastatin 20 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 2.1%75 mg/up to 150 mg + Atorvastatin 40 mg NCT01730040 · Phase 3 · registry result, not featured evidence · combination 0%300 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%150 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%75 mg Q4W NCT02890992 · Phase 2 · registry result, not featured evidence 0%50 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%40 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%30 mg Q2W NCT02890992 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm/ApoB LOFm: Alirocumab F NCT01604824 · Phase 2 · registry result, not featured evidence 16.7%PCSK9 GOFm: Alirocumab From Day 1 NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9 GOFm: Alirocumab From Day 15 NCT01604824 · Phase 2 · registry result, not featured evidence —PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 0%PCSK9GOFm/ApoB LOFm: Alirocumab Fr NCT01604824 · Phase 2 · registry result, not featured evidence 17.4% NCT01576484 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 150 mg Q2Wa nasopharyngitis 13.5% (placebo 13.1%) upper respiratory tract infection 7.4% (placebo 8.6%) injection site reaction 5.9% (placebo 4.2%) NCT01507831 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 show 60 more results150 Q2W nasopharyngitis 13.9% (placebo 11.4%) influenza 12.5% (placebo 2.9%) injection site reaction 8.3% (placebo 5.7%) NCT01617655 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3 75 /up to 150 mg Q2W upper respiratory tract infection 7.7% (placebo 10.3%) nasopharyngitis 7.2% (placebo 4.7%) urinary tract infection 6.3% (placebo 3.7%) NCT01644175 · Phase 3 75/Up to 150 mg Q2W injection site reaction 12.4% (placebo 11%) nasopharyngitis 11.2% (placebo 7.4%) upper respiratory tract infection 6.8% (placebo 8.6%) NCT01623115 · Phase 3 75 mg/up to 150 mg influenza 14.4% (placebo 7.4%) injection site reaction 10.8% (placebo 7.4%) nasopharyngitis 10.8% (placebo 19.8%) NCT01709500 · Phase 3 300 mg Q4W/Up 150 mg Q2W injection site reaction 16.2% (placebo 7%) upper respiratory tract infection 9% (placebo 7.9%) nasopharyngitis 8.5% (placebo 7.9%) NCT01926782 · Phase 3 75 mg Q2W/Up 150 mg Q2W injection site reaction 8.7% (placebo 7%) nasopharyngitis 8.7% (placebo 7.9%) upper respiratory tract infection 7% (placebo 7.9%) NCT01926782 · Phase 3 150 mg Q2W fatigue 14.6% (placebo 9.5%) myalgia 12.2% (placebo 4.8%) diarrhoea 9.8% (placebo 0%) NCT02326220 · Phase 3 150 mg Q2W anaemia 6.9% (placebo 0%) nasopharyngitis 3.4% (placebo 9.5%) arthralgia 0% (placebo 9.5%) NCT02326220 · Phase 3 75/Up to 150 mg Q2W accidental overdose 9.8% upper respiratory tract infection 8.8% hypertension 6.5% NCT01644188 · Phase 3 150 Q2W diarrhoea 6.7% (placebo 0%) headache 4.4% (placebo 8.3%) nasopharyngitis 4.4% (placebo 0%) NCT03156621 · Phase 3 150 Q2W nasopharyngitis 6.7% (placebo 0%) diarrhoea 2.2% (placebo 0%) headache 2.2% (placebo 8.3%) NCT03156621 · Phase 3 Q2W nasopharyngitis 14.3% (placebo 8%) headache 6.1% (placebo 8%) injection site reaction 6.1% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 7.7% (placebo 8%) upper respiratory tract infection 5.8% (placebo 12%) injection site reaction 3.8% (placebo 0%) NCT03510884 · Phase 3 Q2W headache 10.9% (placebo 8%) oropharyngeal pain 8.7% (placebo 0%) injection site reaction 6.5% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 14.3% (placebo 8%) covid-19 8.2% (placebo 0%) nasopharyngitis 6.1% (placebo 8%) NCT03510884 · Phase 3 Q2W low density lipoprotein decreased 8% (placebo 0%) nasopharyngitis 8% (placebo 8%) nausea 8% (placebo 0%) NCT03510884 · Phase 3 Q4W headache 16% (placebo 8%) covid-19 4% (placebo 0%) injection site reaction 4% (placebo 0%) NCT03510884 · Phase 3 nasopharyngitis 6% (placebo 5.6%) hypertension 5.7% (placebo 6.1%) myalgia 5.5% (placebo 5.3%) NCT01663402 · Phase 3 75 Q2W/Up150 Q2W nasopharyngitis 7.5% (placebo 8.2%) headache 6.5% (placebo 7.8%) hypertension 5.9% (placebo 6.7%) NCT02957682 · Phase 4 · registry result, not featured evidence nasopharyngitis 26.2% injection site reaction 6.8% back pain 5.8% NCT02984982 · Phase 4 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W urinary tract infection 5.5% diarrhoea 5.1% arthralgia 2.2% NCT02642159 · Phase 4 · registry result, not featured evidence 150 mg Q2W nasopharyngitis 22.2% alanine aminotransferase increased 11.1% aortic valve incompetence 11.1% NCT03510715 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up to 150 mg Q2W aortic valve incompetence 22.2% headache 22.2% influenza 22.2% NCT03510715 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.8% myalgia 7.1% headache 6.1% NCT02476006 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 9.1% arthralgia 6.1% contusion 3% NCT03415178 · Phase 3 · registry result, not featured evidence urinary tract infection 6.1% arthralgia 4.5% contusion 1.5% NCT03415178 · Phase 3 · registry result, not featured evidence 75 mg Q2W/up150 mg Q2W upper respiratory tract infection 13.3% accidental overdose 6.7% NCT02715726 · Phase 3 · registry result, not featured evidence 150 mg Q2W viral upper respiratory tract infection 15.1% (placebo 16.1%) non-cardiac chest pain 7.5% (placebo 1.8%) back pain 1.9% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 14.8% (placebo 16.1%) pharyngitis 5.6% (placebo 0%) back pain 0% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 150 mg Q4W/Up Q2W viral upper respiratory tract infection 34.2% (placebo 16.1%) fall 7% (placebo 5.4%) back pain 5.1% (placebo 0%) NCT02584504 · Phase 3 · registry result, not featured evidence 75 or 150 mg Q2W viral upper respiratory tract infection 14.2% upper respiratory tract infection 10.8% influenza 9.3% NCT01954394 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 18.8% (placebo 5.2%) back pain 14.6% (placebo 0%) injection site reaction 14.6% (placebo 0%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W viral upper respiratory tract infection 15.1% (placebo 5.2%) fall 13.2% (placebo 1.7%) diarrhoea 10.4% (placebo 3.4%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W cough 17.6% (placebo 0%) arthralgia 15.7% (placebo 6.9%) osteoarthritis 15.7% (placebo 3.4%) NCT02023879 · Phase 3 · registry result, not featured evidence 150 mg Q4W/Up150 mg Q2W injection site reaction 13.8% (placebo 0%) arthralgia 12.1% (placebo 6.9%) headache 8.6% (placebo 6.9%) NCT02023879 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up150 mg Q2W headache 8.7% (placebo 6.9%) viral upper respiratory tract infection 8.7% (placebo 5.2%) muscle spasms 7.8% (placebo 0%) NCT02023879 · Phase 3 · registry result, not featured evidence 75 mg/ up to 150 mg myalgia 24.6% nasopharyngitis 6.3% upper respiratory tract infection 5.6% NCT01709513 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W nasopharyngitis 4.9% (placebo 5.3%) NCT02585778 · Phase 3 · registry result, not featured evidence 75 mg Q2W/Up to 150 mg Q2W dizziness 6.2% (placebo 2.9%) nasopharyngitis 6.2% (placebo 3.9%) diarrhoea 5.2% (placebo 1%) NCT02289963 · Phase 3 · registry result, not featured evidence 75 mg/ Up to 150 mg Q2W nasopharyngitis 45.5% (placebo 36.1%) back pain 12.6% (placebo 5.6%) injection site reaction 12.6% (placebo 4.2%) NCT02107898 · Phase 3 · registry result, not featured evidence 75 mg/up to 150 mg + 10 mg arthralgia 8.2% nausea 6.1% nasopharyngitis 4.1% NCT01730053 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + 20 mg myalgia 7.4% upper respiratory tract infection 7.4% injection site reaction 5.6% NCT01730053 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + Atorvastatin 20 mg muscle spasms 7% back pain 5.3% arthralgia 3.5% NCT01730040 · Phase 3 · registry result, not featured evidence · combination 75 mg/up to 150 mg + Atorvastatin 40 mg back pain 8.5% nasopharyngitis 8.5% accidental overdose 6.4% NCT01730040 · Phase 3 · registry result, not featured evidence · combination 300 mg Q4W acne 20% diarrhoea 20% influenza like illness 20% NCT02890992 · Phase 2 · registry result, not featured evidence 150 mg Q4W nasopharyngitis 20% pyogenic granuloma 20% upper respiratory tract infection 20% NCT02890992 · Phase 2 · registry result, not featured evidence 150 mg Q4W abdominal discomfort 16.7% diarrhoea 16.7% epistaxis 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q2W ligament sprain 11.1% nasopharyngitis 11.1% abdominal pain 5.6% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q2W animal scratch 16.7% arthropod bite 16.7% blood follicle stimulating hormone decreased 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 75 mg Q4W abdominal pain 16.7% asthma 16.7% depressed mood 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 50 mg Q2W diarrhoea 33.3% nasopharyngitis 33.3% alcohol abuse 16.7% NCT02890992 · Phase 2 · registry result, not featured evidence 40 mg Q2W gastroenteritis viral 30% ear infection 10% headache 10% NCT02890992 · Phase 2 · registry result, not featured evidence 40 mg Q2W pharyngitis 25% abdominal discomfort 0% abdominal pain 0% NCT02890992 · Phase 2 · registry result, not featured evidence 30 mg Q2W ear infection 25% epistaxis 25% fall 25% NCT02890992 · Phase 2 · registry result, not featured evidence viral upper respiratory tract infection 40% acne 20% blood bilirubin increased 20% NCT01604824 · Phase 2 · registry result, not featured evidence gastroenteritis 33.3% viral upper respiratory tract infection 33.3% abdominal discomfort 16.7% NCT01604824 · Phase 2 · registry result, not featured evidence headache 28.6% acne 14.3% angina pectoris 14.3% NCT01604824 · Phase 2 · registry result, not featured evidence abdominal discomfort 20% abdominal distension 20% acne 20% NCT01604824 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 28.3% nasopharyngitis 23.9% bronchitis 21.7% NCT01576484 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 82 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alirocumab
show 165 more results
show 86 more results
show 87 more results
show 36 more results
show 25 more results
show 43 more results
show 64 more results
show 62 more results
show 1 more result
show 59 more results
show 25 more results
show 53 more results
+ 93 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alirocumab's landscape · QLC7401's landscape